Jyong Biotech Ltd. Ordinary Shares (MENS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Jyong Biotech Ltd. Ordinary Shares (MENS) has a cash flow conversion efficiency ratio of 0.025x as of December 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-913.00K) by net assets ($-36.52 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See MENS equity to assets ratio to measure how much of total assets are equity-financed.
Jyong Biotech Ltd. Ordinary Shares - Cash Flow Conversion Efficiency Trend (2020–2024)
This chart illustrates how Jyong Biotech Ltd. Ordinary Shares's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore MENS cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
Jyong Biotech Ltd. Ordinary Shares Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Jyong Biotech Ltd. Ordinary Shares ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
GOLFZON Co. Ltd
KQ:215000
|
0.052x |
|
Humm Group Ltd
AU:HUM
|
0.046x |
|
Seoho Electric Co.Ltd
KQ:065710
|
0.065x |
|
Takkt AG
XETRA:TTK
|
-0.017x |
|
Grand Canal Land Public Company Limited
BK:GLAND
|
0.005x |
|
STLLR Gold Inc.
TO:STLR
|
-0.045x |
|
Dazhong Transportation Group Co Ltd B
SHG:900903
|
0.000x |
|
TGE Value Creative Solutions Corp
NYSE:BEBE
|
0.019x |
Annual Cash Flow Conversion Efficiency for Jyong Biotech Ltd. Ordinary Shares (2020–2024)
The table below shows the annual cash flow conversion efficiency of Jyong Biotech Ltd. Ordinary Shares from 2020 to 2024. For the full company profile with market capitalisation and key ratios, see Jyong Biotech Ltd. Ordinary Shares market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-36.52 Million | $-3.62 Million | 0.099x | +30.00% |
| 2023-12-31 | $-34.07 Million | $-2.60 Million | 0.076x | -23.87% |
| 2022-12-31 | $-29.63 Million | $-2.97 Million | 0.100x | +17.88% |
| 2021-12-31 | $-23.32 Million | $-1.98 Million | 0.085x | +50.27% |
| 2020-12-31 | $-19.20 Million | $-1.09 Million | 0.057x | -- |
About Jyong Biotech Ltd. Ordinary Shares
Jyong Biotech Ltd., a science-driven biotechnology company, develops and commercializes plant-derived drugs for the treatment of urinary system diseases in the United States, the European Union, and Asia. It develops MCS-2 for the treatment of benign prostate hyperplasia/lower urinary tract symptoms; PCP for treating prostate cancer; and interstitial cystitis (IC) for the treatment of IC/bladder … Read more